Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,572 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biological Control Clear all
Not listed No phase listed Observational

Phenotypic and Genetic Assessment of Tracheal and Esophageal Birth Defects in Patients

NCT03455881
View directory record Official record
Conditions
Tracheoesophageal Fistula, Esophageal Atresia, Laryngeal Cleft, Tracheal Stenosis, Bronchial Stenosis, Esophageal Bronchus, Congenital High Airway Obstruction Syndrome
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

PROvenge Treatment and Early Cancer Treatment

NCT00779402
View directory record Official record
Conditions
Prostate Cancer
Interventions
Control, Sipuleucel-T
Other · Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
18
States / cities
Berkeley, California • Laguna Hills, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Biologics Anchoring Study

NCT03026153
View directory record Official record
Conditions
Moderate-to-severe Psoriasis
Interventions
Control Group Oral Survey 1, Intervention Group Oral Survey 2
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Phase 3 Interventional

A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT00047645
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Interferon-gamma 1b
Drug
Lead sponsor
InterMune
Industry
Eligibility
20 Years to 79 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 2, 2007 · Synced Oct 21, 2026, 2:19 PM EDT
Active, not recruiting Phase 4 Interventional

Connective Tissue Matrix for Rotator Cuff Tendinopathy

NCT06160427
View directory record Official record
Conditions
Tendinopathy, Shoulder Pain, Rotator Cuff Tendinitis, Rotator Cuff Tendinosis
Interventions
CTM Boost, PRP
Biological
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania • Wexford, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants

NCT01576003
View directory record Official record
Conditions
Bloodstream Infections, Short Bowel Syndrome, Development, Nutrition, Biological Markers
Interventions
Glutamine, L-alanine
Drug · Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Weeks to 12 Months
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Results available

Placebo Controlled Trial of Botulinum Toxin for Gastroparesis

NCT00372970
View directory record Official record
Conditions
Gastroparesis
Interventions
Botulinum toxin A, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Oct 21, 2026, 2:19 PM EDT
Terminated Phase 4 Interventional Results available

An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects

NCT02793154
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide, Albiglutide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

VAXCHORA Pediatric Study to Assess Safety and Immunogenicity

NCT03220737
View directory record Official record
Conditions
Cholera (Disorder)
Interventions
VAXCHORA (Cholera Vaccine, Live, Oral), Placebo
Biological · Other
Lead sponsor
Bavarian Nordic
Industry
Eligibility
2 Years to 17 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
10
States / cities
Atlanta, Georgia • Lenexa, Kansas • Wichita, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine

NCT01005407
View directory record Official record
Conditions
Healthy
Interventions
HEPLISAV and/or Placebo, Engerix-B
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
40 Years to 70 Years
Enrollment
2,452 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
29
States / cities
Huntsville, Alabama • San Diego, California • Santa Ana, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 21, 2026, 2:19 PM EDT
Terminated Phase 2 Interventional

Helping Veterans Quit Smoking by Improving Their Sleep

NCT01267032
View directory record Official record
Conditions
Smoking
Interventions
Integrated Care, Cognitive-Behavioral Treatment for Insomnia, Desensitization Treatment for Insomnia
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris

NCT04883736
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin Gel Microsphere, 0.1%, RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
973 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 21, 2026, 2:19 PM EDT
Withdrawn Phase 2 Interventional

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

NCT04482933
View directory record Official record
Conditions
Neoplasms, High Grade Glioma, Glioblastoma Multiforme, Malignant Glioma of Brain, Anaplastic Astrocytoma of Brain, High-grade Glioma, Anaplastic Glioma, Giant Cell Glioblastoma
Interventions
Biological G207
Biological
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Aurora, Colorado • New York, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Biopsychosocial Effect of Service Dog Training on Post-traumatic Stress (PTS) and Post Concussive Symptoms

NCT03907254
View directory record Official record
Conditions
Post-traumatic Stress Disorder, Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
Service Dog Training Program
Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

NCT01064401
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
BIIB019 (Daclizumab High Yield Process), Interferon beta-1a Placebo, Interferon beta-1a, Daclizumab High Yield Process Placebo
Biological · Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
46
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device

NCT02146781
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
CryJ2-DNA-LAMP plasmid vaccine by intradermal injection, Saline Control
Biological · Other
Lead sponsor
Immunomic Therapeutics, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Use of Topical Subgingival Application of Simvastatin Gel in the Treatment of Peri-Implant Mucositis

NCT03400475
View directory record Official record
Conditions
Peri-implant Mucositis
Interventions
Simvastatin, Placebo
Drug · Other
Lead sponsor
Ahmed Mohamed Mahrous
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 21, 2026, 2:19 PM EDT
Terminated Phase 3 Interventional Results available

Study of Rifampicin in Multiple System Atrophy

NCT01287221
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Rifampicin, placebo
Drug
Lead sponsor
Phillip Low
Other
Eligibility
30 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2014 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Early FMT for C.Difficile

NCT02465463
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Fecal microbiota transplant (FMT), flexible sigmoidoscopy
Procedure · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 79 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Phase 3 Interventional

Evaluation of Fibrin Sealant 2 in Retroperitoneal or Intra-Abdominal Surgery

NCT00307515
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Fibrin Sealant 2 (FS2), Oxidized Regenerated Cellulose (Surgicel)
Drug · Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
Not listed
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
16
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2009 · Synced Oct 21, 2026, 2:19 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

NCT04499248
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
42
States / cities
Sun City, Arizona • Glendale, California • Inglewood, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 21, 2026, 2:19 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

NCT06740630
View directory record Official record
Conditions
Chickenpox
Interventions
Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investigational varicella vaccine_Lot 3, Marketed varicella vaccine_Lot 1, Marketed varicella vaccine_Lot 2, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
1,840 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
59
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Sherwood, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

NCT00770211
View directory record Official record
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Englewood, Colorado • Aventura, Florida • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults

NCT02057263
View directory record Official record
Conditions
Hepatitis B
Interventions
Alendronate, Hepatitis B Vaccine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 21, 2026, 2:19 PM EDT